The 2016 calendar year might now be drawing to a close, but I think investors are still being presented with some really exciting opportunities for the year ahead.
Here are six of my favourite growth shares heading into 2017:
Speedcast International Ltd (ASX: SDA) – Shares of this leading satellite communications company have been slammed recently on the back of a large acquisition. However, if the company can successfully deliver on its ambitious forecasts, I think the shares will rebound strongly from here.
Blackmores Limited (ASX: BKL) – It hasn't been a great year for this former market darling, but the shares will trade significantly higher if the vitamin company can regain its sales momentum in the second half of FY17. The Asian demand story remains intact and Blackmores is still well placed to capitalise on the opportunity.
Vocus Communications Limited (ASX: VOC) – Although the market has seemingly written off the company based on a weaker-than-expected trading update, it's hard to go past the shares from a valuation perspective. While not without risk, I feel 2017 could be a good year for Vocus as long as it meets its recently issued guidance.
Cochlear Limited (ASX: COH) – Cochlear shares have taken a breather recently and I believe this has presented longer term investors with a decent entry point. The company is forecasting another strong year of growth and investors will benefit if the Australian dollar continues to fall further from here.
BWX Ltd (ASX: BWX) – Although the natural skincare company is still in the early stages of establishing its export market strategy, it has already established a strong following amongst Asian consumers. This is quite an exciting position for BWX and investors now have the opportunity to own the shares at a fairly attractive valuation.
CSL Limited (ASX: CSL) – 2016 has been a year of surprisingly weak returns for CSL shareholders, yet I wouldn't be betting against the biopharmaceutical giant in 2017. The company's influenza business' turnaround is now on track and earnings should be boosted by the addition of new treatments and entry into new markets.
